Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.

Ardini E, Menichincheri M, Banfi P, Bosotti R, De Ponti C, Pulci R, Ballinari D, Ciomei M, Texido G, Degrassi A, Avanzi N, Amboldi N, Saccardo MB, Casero D, Orsini P, Bandiera T, Mologni L, Anderson D, Wei G, Harris J, Vernier JM, Li G, Felder E, Donati D, Isacchi A, Pesenti E, Magnaghi P, Galvani A.

Mol Cancer Ther. 2016 Apr;15(4):628-39. doi: 10.1158/1535-7163.MCT-15-0758. Epub 2016 Mar 3.

2.

Correction: Immunological Characterization of Whole Tumour Lysate-Loaded Dendritic Cells for Cancer Immunotherapy.

Rainone V, Martelli C, Ottobrini L, Biasin M, Texido G, Degrassi A, Borelli M, Lucignani G, Trabattoni D, Clerici M.

PLoS One. 2016 Mar 2;11(3):e0151008. doi: 10.1371/journal.pone.0151008. eCollection 2016. No abstract available.

3.

Immunological Characterization of Whole Tumour Lysate-Loaded Dendritic Cells for Cancer Immunotherapy.

Rainone V, Martelli C, Ottobrini L, Biasin M, Texido G, Degrassi A, Borelli M, Lucignani G, Trabattoni D, Clerici M.

PLoS One. 2016 Jan 21;11(1):e0146622. doi: 10.1371/journal.pone.0146622. eCollection 2016. Erratum in: PLoS One. 2016;11(3):e0151008. Texido, Gemma [added]; Degrassi, Anna [added].

4.

Direct involvement of CD56 in cytokine-induced killer-mediated lysis of CD56+ hematopoietic target cells.

Valgardsdottir R, Capitanio C, Texido G, Pende D, Cantoni C, Pesenti E, Rambaldi A, Golay J, Introna M.

Exp Hematol. 2014 Dec;42(12):1013-21.e1. doi: 10.1016/j.exphem.2014.08.005. Epub 2014 Sep 6.

PMID:
25201755
5.

Drug resistance.

Texidó G, Moll J.

Drug Discov Today Technol. 2014 Mar;11:1-3. doi: 10.1016/j.ddtec.2014.03.013. No abstract available.

PMID:
24847646
6.

The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia.

Casolaro A, Golay J, Albanese C, Ceruti R, Patton V, Cribioli S, Pezzoni A, Losa M, Texido G, Giussani U, Marchesi F, Amboldi N, Valsasina B, Bungaro S, Cazzaniga G, Rambaldi A, Introna M, Pesenti E, Alzani R.

PLoS One. 2013;8(3):e58424. doi: 10.1371/journal.pone.0058424. Epub 2013 Mar 8.

7.

In vivo target validation by inducible RNAi in human xenograft mouse models.

Mazzoletti M, Texidó G.

Methods Mol Biol. 2013;986:325-37. doi: 10.1007/978-1-62703-311-4_20.

PMID:
23436421
8.

Genetically engineered animal models for in vivo target identification and validation in oncology.

Texidó G.

Methods Mol Biol. 2013;986:281-305. doi: 10.1007/978-1-62703-311-4_18. Review.

PMID:
23436419
9.

In vivo imaging of early stage apoptosis by measuring real-time caspase-3/7 activation.

Scabini M, Stellari F, Cappella P, Rizzitano S, Texido G, Pesenti E.

Apoptosis. 2011 Feb;16(2):198-207. doi: 10.1007/s10495-010-0553-1.

PMID:
21082356
10.

Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D)LA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging.

Degrassi A, Russo M, Nanni C, Patton V, Alzani R, Giusti AM, Fanti S, Ciomei M, Pesenti E, Texido G.

Mol Cancer Ther. 2010 Mar;9(3):673-81. doi: 10.1158/1535-7163.MCT-09-0726. Epub 2010 Mar 2.

11.

PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.

Carpinelli P, Ceruti R, Giorgini ML, Cappella P, Gianellini L, Croci V, Degrassi A, Texido G, Rocchetti M, Vianello P, Rusconi L, Storici P, Zugnoni P, Arrigoni C, Soncini C, Alli C, Patton V, Marsiglio A, Ballinari D, Pesenti E, Fancelli D, Moll J.

Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3158-68.

12.

Magnetic resonance imaging and histopathological characterization of prostate tumors in TRAMP mice as model for pre-clinical trials.

Degrassi A, Russo M, Scanziani E, Giusti A, Ceruti R, Texido G, Pesenti E.

Prostate. 2007 Mar 1;67(4):396-404.

PMID:
17187397
13.

FGF2 signaling is required for the development of neuronal circuits regulating blood pressure.

Dono R, Faulhaber J, Galli A, Zuniga A, Volk T, Texido G, Zeller R, Ehmke H.

Circ Res. 2002 Jan 11;90(1):E5-E10.

PMID:
11786528
15.

Mice reconstituted with DNA polymerase beta-deficient fetal liver cells are able to mount a T cell-dependent immune response and mutate their Ig genes normally.

Esposito G, Texido G, Betz UA, Gu H, Müller W, Klein U, Rajewsky K.

Proc Natl Acad Sci U S A. 2000 Feb 1;97(3):1166-71.

16.

The B-cell-specific Src-family kinase Blk is dispensable for B-cell development and activation.

Texido G, Su IH, Mecklenbräuker I, Saijo K, Malek SN, Desiderio S, Rajewsky K, Tarakhovsky A.

Mol Cell Biol. 2000 Feb;20(4):1227-33.

17.

Impaired cerebral cortex development and blood pressure regulation in FGF-2-deficient mice.

Dono R, Texido G, Dussel R, Ehmke H, Zeller R.

EMBO J. 1998 Aug 3;17(15):4213-25.

18.

The molecular mechanism of B cell activation by toll-like receptor protein RP-105.

Chan VW, Mecklenbräuker I, Su I, Texido G, Leitges M, Carsetti R, Lowell CA, Rajewsky K, Miyake K, Tarakhovsky A.

J Exp Med. 1998 Jul 6;188(1):93-101.

19.

Somatic hypermutation occurs in B cells of terminal deoxynucleotidyl transferase-, CD23-, interleukin-4-, IgD- and CD30-deficient mouse mutants.

Texidó G, Jacobs H, Meiering M, Kühn R, Roes J, Müller W, Gilfillan S, Fujiwara H, Kikutani H, Yoshida N, Amakawa R, Benoist C, Mathis D, Kishimoto T, Mak TW, Rajewsky K.

Eur J Immunol. 1996 Aug;26(8):1966-9. No abstract available.

PMID:
8765046
20.

Transgene CD23 expression on lymphoid cells modulates IgE and IgG1 responses.

Texido G, Eibel H, Le Gros G, van der Putten H.

J Immunol. 1994 Oct 1;153(7):3028-42.

PMID:
8089484
21.

Mice deficient in CD23 reveal its modulatory role in IgE production but no role in T and B cell development.

Stief A, Texido G, Sansig G, Eibel H, Le Gros G, van der Putten H.

J Immunol. 1994 Apr 1;152(7):3378-90.

PMID:
8144922
22.

Immunoglobulin E-binding site in Fc epsilon receptor (Fc epsilon RII/CD23) identified by homolog-scanning mutagenesis.

Bettler B, Texido G, Raggini S, Rüegg D, Hofstetter H.

J Biol Chem. 1992 Jan 5;267(1):185-91.

Supplemental Content

Loading ...
Support Center